Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372279 | 0.81 | HDAC4 (0.39) | KDM4EKMT2ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL27606683 | 0.81 | KDM4E (0.41) | KDM4EKMT2ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL372283 | 0.80 | MGAM (0.42) | KDM4EKMT2ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL21294950 | 0.78 | MAPT (0.41) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL6720687 | 0.77 | KDM4E (0.36) | KDM4EKMT2ASMN1; SMN2MGAMRAB9A | |
| SCHEMBL5998390 | 0.74 | KDM4E (0.42) | KDM4EKMT2ASMN1; SMN2MGAMSCN9A | |
| SCHEMBL372278 | 0.72 | MGAM (0.41) | KDM4EKMT2ASMN1; SMN2HDAC4HDAC1 | |
| SCHEMBL28422766 | 0.71 | ELANE (0.30) | — | |
| SCHEMBL28517755 | 0.71 | UGT2B7 (0.44) | KDM4EKMT2ASMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL5200183 | 0.71 | MGAM (0.50) | KDM4EKMT2ASMN1; SMN2HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272500-B1 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2005-05-04 | — | — | EP | claimed |
| US-6437106-B1 | ALKYLATION WITH ALKENYL CARBONATE OR CARBAMATE IN PRESENCE OF PALLADIUM CATALYST AND PHOSPHINE; CYCLIZATION | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | claimed |
| EP-2261212-B1 | Preparation of quinoline-substituted carbamate derivatives | ABBVIE INC (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2409964-B1 | Process for the preparation of carbonate derivatives | ABBOTT LAB (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-1192139-B1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2409964-A2 | Preparation of substituted carbonate and carbamate derivatives | Abbott Laboratories (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2261212-A2 | Preparation of quinoline-substituted carbonate and carbamate derivatives | Abbott Laboratories (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1345954-B1 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7271155-B2 | 9A, 11-2C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-6579986-B2 | Metal-catalyzed coupling reactions for 6-o-substituted macrolide antibiotics | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| US-20020165390-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-11-07 | — | — | US | disclosed |
| US-6455680-B1 | PROTECTING A KETONE OF A KETONE-CONTAINING ERYTHROMYCIN DERIVATIVE AS AN ARYL THIOIMINE (AR-S-N=) BY REACTING THE KETONE WITH A HYDROXYLAMINE TO FORM AN OXIME, AND THEN REACTING WITH A TRIALKYL PHOSPHINE AND AN ARYL DISULFIDE | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | ABBVIE INC. | 2002-08-22 | — | — | US | disclosed |
| US-6437106-B1 | ALKYLATION WITH ALKENYL CARBONATE OR CARBAMATE IN PRESENCE OF PALLADIUM CATALYST AND PHOSPHINE; CYCLIZATION | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6417366-B2 | CHEMICAL INTERMEDIATE FOR MACROLACTONE ANTIBIOTIC | ABBOTT LABORATORIES | 2002-07-09 | — | — | US | disclosed |
| EP-1192139-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | Abbott Laboratories (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | ABBVIE INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001000582-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | CYP3A7, CYP2C8, CYP51A1 | KDM4E 224/4885KMT2A 1488/4885SMN1; SMN2 3555/4885 |
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | CYP2C9, CYP2B6, POR | KDM4E 541/4885KMT2A 2229/4885SMN1; SMN2 4157/4885 |
| US-20020165390-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | KDM4E 211/4885KMT2A 567/4885SMN1; SMN2 4246/4885 |
| US-20020013468-A1 | Preparation of quinoline-substituted carbonate and carbamate derivatives | CA7, CA6, CA4 | KDM4E 211/4885KMT2A 567/4885SMN1; SMN2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.